# Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

> **NCT02496585** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Lung Cancer
- Lung Metastases

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Prednisone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02496585
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-08
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-04-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02496585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02496585, "Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02496585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*